Bionano Genomics (Bionano Genomics) Cash-to-Debt : 1.28 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Bionano Genomics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Bionano Genomics's cash to debt ratio for the quarter that ended in Dec. 2023 was 1.28.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Bionano Genomics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Bionano Genomics's Cash-to-Debt or its related term are showing as below:

BNGO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15 Med: 1.56 Max: 23.43
Current: 1.28

During the past 8 years, Bionano Genomics's highest Cash to Debt Ratio was 23.43. The lowest was 0.15. And the median was 1.56.

BNGO's Cash-to-Debt is ranked worse than
56.45% of 861 companies
in the Medical Devices & Instruments industry
Industry Median: 1.87 vs BNGO: 1.28

Bionano Genomics Cash-to-Debt Historical Data

The historical data trend for Bionano Genomics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Bionano Genomics Cash-to-Debt Chart

Bionano Genomics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.86

2.36

23.43

9.70

1.28

Bionano Genomics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															9.70	8.58	7.23	6.27	1.28

Competitive Comparison of Bionano Genomics's Cash-to-Debt

For the Medical Instruments & Supplies subindustry, Bionano Genomics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bionano Genomics's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Bionano Genomics's Cash-to-Debt falls into.

Bionano Genomics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Bionano Genomics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	101.888	/	(72.238	+	7.175)
	=	1.28

Bionano Genomics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	101.888	/	(72.238	+	7.175)
	=	1.28

Bionano Genomics (NAS:BNGO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Bionano Genomics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Bionano Genomics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Bionano Genomics (Bionano Genomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bionano Genomics Inc (NAS:BNGO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

BNGO:Mexico

Address

9540 Towne Centre Drive, Suite 100, San Diego, CA, USA, 92121

Website

https://bionano.com

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas.

Executives

Gulsen Kama	officer: Chief Financial Officer	C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Hannah Mamuszka	director	C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
R. Erik Holmlin	director, officer: President and CEO	4088 COMMERCIAL AVE., NORTHBROOK IL 60062
Christopher P. Stewart	officer: Chief Financial Officer	C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Jonathan V. Dixon	officer: General Counsel	C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Yvonne Linney	director	C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
David L Barker	director	9885 TOWNE CENTRE DR, SAN DIEGO CA 92121
Aleksandar Rajkovic	director	9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Vincent Jung-fai Wong	director	C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Soheil Shams	officer: Chief Informatics Officer	C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Richard Shippy	officer: Chief Business Officer	C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Robert J Priar	officer: Chief Commercial Officer	C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Alka Chaubey	officer: Chief Medical Officer	C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Heather Adams	officer: Chief Administrative Officer	C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Kristiina Md Vuori	director	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011